Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose PTCy for GVHD Prophylaxis in Hematological Malignancies
NCT06926595Phase 2Recruiting
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Mar 2026
- Primary completion
- Nov 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoints: Number of Subjects Without Grade III/IV Acute Graft-Versus-Host Disease (GVHD) at 1 year, Number of Subjects Without Chronic Graft-Versus-Host Disease (GVHD) Requiring Systemic Treatment at 1 year and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06926595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926595.